Abiomed-backed Shockwave Medical has raised approximately $97m in an oversubscribed initial public offering, before its shares climbed more than 85% by the end of Friday.

Tencent invested $8m as the Chinese online brokerage floated at the top of its range in the US, at a valuation of more than $1.3bn.

Taikang and WuXi-backed CStone Pharmaceuticals has priced its shares near the middle of its proposed range to raise $285m in proceeds at a valuation of $1.5bn.

Nan Fung-backed mitochondrial therapy developer Stealth BioTherapeutics floated at the foot of its range to raise $78m, having disclosed $100m in financing last June.

The Taiho and Eli Lilly-backed immunotherapy developer floated in the middle of its range to raise $75.6m, valuing it at about $334m.

Nan Fung-backed biopharmaceutical company Stealth Bio has filed for an IPO that could bring in almost $87m if it floats at the top of the range.

The AbbVie, Eli Lilly, Amgen, Merck & Co and Alphabet-backed neurodegenerative disease drug developer is floating in the middle of its range.

A leading company in the e-signature and digital transaction management space, San Francisco-based DocuSign went public in April last year, with a market capitalization of $4.4bn.

Maoyan is floating in Hong Kong at the bottom of its range, in an offering that will provide exits to Enlight, Tencent and Meituan Dianping.

Aptus-backed neurodegenerative-focused company Alzheon has withdrawn its second attempt at initial public offering, less than year after cancelling its first bid.